AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
AbbVie and Genmab reported positive Phase III trial results for epcoritamab combined with R-CHOP in DLBCL patients. The combination showed a 51% reduction in progression or death risk versus R-CHOP alone. The companies plan to share full data and consult regulators. Epcoritamab is jointly developed and not yet approved for this use.
How this was made
The 30-second read
Why it matters
The data shows a statistically significant improvement in progression‑free survival, a 51% risk reduction versus standard R‑CHOP, indicating a potentially practice‑changing therapy.
Market read
First report of pivotal trial success; likely to move both stocks and influence the oncology biotech sector.
What to watch
Potential competition from other bispecifics and the need for FDA approval timelines.
Background
The article reports first‑time disclosure of Phase III trial results for epcoritamab, a bispecific antibody targeting DLBCL.
Ticker impact
AbbVie announced positive Phase III EPCORE DLBCL-2 trial data for epcoritamab combined with R-CHOP.
upward pressure as investors price in potential future sales.
Phase III data with 51% risk reduction is material and may accelerate regulatory filings.
Genmab co-developed epcoritamab and reported the same positive Phase III trial outcomes.
upward pressure driven by increased commercial potential.
Joint developer of the trial drug; positive data enhances its valuation and partnership prospects.
Market effects
Strengthens the broader oncology biotech sector and may lift peers developing bispecific antibodies.
Positive for US and European biotech markets where both companies are listed.
Adds confidence to investors tracking cancer therapy pipelines worldwide.
Counterpoint
If regulatory scrutiny intensifies or safety concerns emerge, the rally could be limited.
Key entities
- CompanyAbbVie
US‑listed biopharma developing epcoritamab.
- CompanyGenmab
Co‑developer of epcoritamab, listed on Nasdaq.
